FMP
EURONEXT
5.7 EUR
-0.07 (-1.23%)
Mr. Laurent Levy Ph.D.
Healthcare
Biotechnology
https://www.nanobiotix.com
EURONEXT
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
N/A
FR0011341205
N/A
60 rue de Wattignies
33 1 40 26 04 70
FR
101
Oct 29, 2012
-
EURONEXT
Biotechnology
Healthcare
-
FR0011341205
FR
5.7
1.27
76.68k
268.53M
-
1.612-10.4
-1.18
-
-
-
-
-3.39
-
https://www.nanobiotix.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.